Current research status of sitagliptin in treatment of type 2 diabetes mellitus

doi:10.3877/cma.j.issn.1674-0785.2017.16.009

Abstract

Abstract:

Sitagliptin as the earliest dipeptidyl peptidase-4 inhibitor marketed in China, when used alone or in combination with other drugs, can safely and effectively improve blood glucose, with little risk of hypoglycemia and weight gain among the patients. In addition to its hypoglycemic effect, sitagliptin also has the effects of cardiovascular protection and improvement of microvascular disease. This paper aims to review the current research status of sitagliptin in the treatment of type 2 diabetes mellitus.

Key words: Sitagliptin, Diabetes mellitus, Blood glucose variability

Jun Chen, Hao Qi. Current research status of sitagliptin in treatment of type 2 diabetes mellitus[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(16): 2149-2151.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.16.009

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I16/2149

References 29

[1]	王汝龙, 母义明, 胡欣. 2型糖尿病治疗的新选择——DPP-4抑制剂 [J]. 中国药学杂志, 2014, 49(8): 702-704.
[2]	邢晓敏, 苏乐群. 二肽基肽酶Ⅳ抑制剂治疗2型糖尿病肥胖患者的临床研究进展 [J]. 中国药房, 2015, 26(5): 715-718.
[3]	Takahara M, Shiraiwa T, Kaneto H, et al. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy [J]. Endocr J, 2012, 59(12): 1131-1136.
[4]	Mori Y, Taniguchi Y, Matsuura K, et al. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring [J]. Diabetes Technol Ther, 2011, 13(7): 699-703.
[5]	陈浩, 冯英, 田绍巍, 等. 西格列汀治疗老年2型糖尿病临床有效性研究 [J]. 中国现代药物应用, 2016, 10(13): 160.
[6]	李晶晶. 西格列汀与阿卡波糖治疗2型糖尿病临床疗效比较研究[A]// 中国中药杂志2015/专集:基层医疗机构从业人员科技论文写作培训会议论文集[C]. 2016: 2.
[7]	向勤, 吴逊. 初诊2型糖尿病应用西格列汀与二甲双胍治疗对血糖波动及微炎症状态的影响 [J]. 海南医学院学报, 2016, 22(15): 1653-1655, 1659.
[8]	Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients [J]. Diabetes Res Clin Pract, 2012, 98(1): 51-60.
[9]	张坤, 任巧华, 吴韬, 等. 西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床观察 [J]. 中国药房, 2016, 27(17): 2364-2366.
[10]	Osonoi T, Saito M, Tamasawa A, et al. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: A prospective randomized study [J]. Exp Opin Pharmacother, 2014, 15(10): 1325-1335.
[11]	张敏, 陈景言, 陈树, 等. 拜糖平联合西格列汀治疗餐后血糖控制不佳2型糖尿病患者的临床疗效观察 [J]. 中国糖尿病杂志, 2015, 23(8): 735-738.
[12]	Mori Y, Taniguchi Y, Miyazaki S, et al. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy [J]. Diabetes Technol Ther, 2013, 15(3): 237-240.
[13]	Tajiri Y, Kawano S, Hirao S, et al. Adding of Sitagliptin on insulin therapy effectively and safely reduces a hemoglobin a1c level and glucose fluctuation in japanese patients with type 2 diabetes [J]. Int Sch Res Noticea, 2014, 2014: 639489.
[14]	Shimoda S, Iwashita S, Ichimori S, et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy [J]. Endocr J, 2013, 60(10): 1207-1214.
[15]	Harashima S.-l., Tanaka D., Yamane S. et al. Efficacy and safety of switching from basal insulin to Sitagliptin in Japanese type 2 diabetes patients [J]. Horm Metab Res, 2013, 45(3): 231-238.
[16]	徐芬娟, 宣少平, 张青森, 等. 西格列汀联合预混胰岛素对2型糖尿病患者血糖波动的影响 [J]. 中国临床药理学杂志, 2015, 31(9): 689-692.
[17]	曾生, 陈笑冰, 金传奉, 等. 西格列汀联合甘精胰岛素对2型糖尿病患者血糖水平影响观察 [J]. 药物流行病学杂志, 2015, 24(11): 648-650, 668.
[18]	胡军, 许腾, 高啸, 等. 西格列汀联合地特胰岛素治疗老年2型糖尿病的疗效及安全性观察 [J]. 中国医院药学杂志, 2015, 35(10): 949-951.
[19]	Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-Ⅳ inhibitors [J]. Atherosclerosis, 2013, 227(2): 349-354.
[20]	Hage C, Brismar K, Efendic S, et al. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities-the BEGAMI study [J]. J Int Med, 2013, 273(4): 410-421.
[21]	VanGenugten RE, Möller-Goede DL, VanRaalte DH, et al. Extra-pancreatic effects of incretin-based therapies: Potential benefit for cardiovascular-risk management in type 2 diabetes [J]. Diabetes Obes Metab, 2013, 15(7): 593-606.
[22]	汝颖, 任安, 叶山东, 等. 二肽基肽酶-4抑制剂心血管保护作用的研究进展 [J]. 中华内分泌代谢杂志, 2014, 30(3): 258-260.
[23]	张坤, 任巧华, 吴韬, 等. 西格列汀对2型糖尿病心血管并发症相关危险因素及标志物的影响 [J]. 临床误诊误治, 2016, 29(5): 94-98.
[24]	王菁楠, 顾明君, 赵泽飞, 等. 西格列汀对2型糖尿病肾损害患者尿微量白蛋白的影响 [J]. 中国新药与临床杂志, 2013, 32(4): 289-292.
[25]	郝清顺, 刘玉苓, 费大东. 西格列汀对初诊2型糖尿病并发早期糖尿病肾病患者的影响 [J]. 泰山医学院学报, 2015, 36(9): 989-991.
[26]	Pendergrass M, Fenton C, Haffner SM, et al. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis [J]. Diabetes Obes Metab, 2012, 14(7): 596-600.
[27]	邢颖, 郑策, 甄健存. 二肽基肽酶DPP-4抑制剂—西格列汀治疗2型糖尿病的安全性国内外文献分析 [J]. 中国医院药学杂志, 2012, 32(6): 480-481.
[28]	王娟. 西格列汀治疗2型糖尿病的临床研究进展讨论 [J]. 现代诊断与治疗, 2016, 27(15): 2906-2907, 2940.
[29]	Liao KF, Lin CL, Lai SW, et al. Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: a population-based case-control study in Taiwan [J]. Europ J Int Med, 2016, 27: 76-79.

Please choose a citation manager

Content to export